IDH1 and central nervous system cancer: With respect of IDH mutation status or 1p/19q codeletion status, it has been reported that the glioma patients with IDH mutation or 1p/19q codeletion always exhibit more satisfactory prognosis (Alentorn et al., 2014; Brat et al., 2015).